Results 311 to 320 of about 111,765 (333)

Proteomic Profiling of the Large‐Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling

Arthritis &Rheumatology, EarlyView.
Objective Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large‐vessel vasculitis (LVV), can result in serious morbidity. Understanding the molecular basis of LVV should aid in developing better biomarkers and treatments. Methods Plasma proteomic profiling of 184 proteins was performed in two cohorts. Cohort 1 included
Robert T. Maughan, Erin Macdonald‐Dunlop, Lubna Haroon‐Rashid, Louise Sorensen, Natalie Chaddock, Shauna Masters, Andrew Porter, Marta Peverelli, Charis Pericleous, Andrew Hutchings, James Robinson, Taryn Youngstein, Raashid A. Luqmani, Justin C. Mason, Ann W. Morgan, James E. Peters   +15 more
wiley   +1 more source

Genome‐Wide Aggregated Trans Effects Analysis Identifies Genes Encoding Immune Checkpoints as Core Genes for Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective The sparse effector “omnigenic” hypothesis postulates that the polygenic effects of common single nucleotide polymorphisms (SNPs) on a typical complex trait are mediated by trans effects that coalesce on expression of a relatively sparse set of core genes.
Athina Spiliopoulou, Andrii Iakovliev, Darren Plant, Megan Sutcliffe, Seema Sharma, Cankut Cubuk, Myles Lewis, Costantino Pitzalis, Anne Barton, Paul M. McKeigue   +9 more
wiley   +1 more source

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs. those with normal renal function. Methods Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) not on dialysis were ...
Chandrali S. Bhattacharya, Hans Ericsson, Susanne Johansson, Joanna Parkinson, Simina M. Boca, Ye Yang, Maria Heijer, Greggory Housler, Maria Leonsson‐Zachrisson, Judith Hartleib‐Geschwindner, Patricia Ely Pizzato   +10 more
wiley   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

The tacrolimus concentration‐to‐dose ratio is associated with kidney function in heart transplant recipients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Heart transplantation (HT) is frequently complicated by chronic kidney disease, of which tacrolimus‐related nephrotoxicity is an important cause. In kidney and liver transplant recipients, fast tacrolimus metabolism (defined as a low concentration‐to‐dose [C0/D] ratio), negatively affects kidney function.
Maaike R. Schagen, Teun B. Petersen, Boris C. A. Seijkens, Jasper J. Brugts, Kadir Caliskan, Alina A. Constantinescu, Brenda C. M. de Winter, Isabella Kardys, Dennis A. Hesselink, Olivier Manintveld   +9 more
wiley   +1 more source

The Known and Unknown About Female Reproductive Tract Mucus Rheological Properties

BioEssays, EarlyView.
Mucus viscosity changes as spermatozoa travel through the female reproductive tract to the egg in humans, bovines, mice, and other mammals. These changes may aid in spermatozoa navigation. However, limited information is available on the viscoelastic properties of female reproductive tract mucus, and consistent measurement techniques are lacking ...
Luke Achinger, Derek F. Kluczynski, Abigail Gladwell, Holly Heck, Faith Zhang, Ethan Good, Alexis Waggoner, Mykala Reinhart, Megan Good, Dawson Moore, Dennis Filatoff, Supriya Dhar, Elisa Nigro, Lucas Flanagan, Sunny Yadav, Trinity Williams, Aniruddha Ray, Tariq A. Shah, Matthew W. Liberatore, Tomer Avidor‐Reiss   +19 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glycoprotein VI - novel target in antiplatelet medication

Pharmacology & Therapeutics, 2021
Subendothelial collagen exposed to platelets after rupture of atherosclerotic plaques is the main trigger of platelet activation und acute arterial thrombotic occlusion leading to myocardial infarction or ischemic stroke. An efficacious antiplatelet therapy is essential to prevent atherothrombotic events.
Borst, Oliver, Gawaz, Meinrad Paul
openaire   +4 more sources

Focusing on plasma glycoprotein VI

Thrombosis and Haemostasis, 2012
SummaryNew methods for analysing both platelet and plasma forms of the platelet-specific collagen receptor, glycoprotein VI (GPVI) in experimental models or human clinical samples, and the development of the first therapeutic compounds based on dimeric soluble GPVI-Fc or anti-GPVI antibody-based constructs, coincide with increased understanding of the ...
Jane Frances Arthur, Elizabeth E. Gardiner, Mohammad Al-Tamimi, Robert K. Andrews   +3 more
openaire   +3 more sources